Document:

MUTUAL COMPENSATION SCHEDULE

 

This
Compensation Schedule (this “Schedule”) is made and effective as of March 27, 2017 (the “Effective
Date”), by and between AmericaTowne, Inc., a Delaware corporation and reporting company under the rules promulgated by the
United States Securities and Exchange Commission, with a mailing address for notice purposes of 4700 Homewood Court, Suite 100
in Raleigh, North Carolina 27609 (“AmericaTowne”) and Mr. Mabiala Phuati Josue with an address for notice
purposes of 34 Banku Avenue Mombele - Commune of Limete, Kinshasa - Democratic Republic of Congo (the “Service Provider”),
and is incorporated into and merged with the International Trade Center Service Provider Agreement between the Service Provider
and AmericaTowne (the “Agreement”.) AmericaTowne and the Service Provider may be defined singularly as a “Party”
or collectively as the “Parties.”

 

WHEREAS, until further
written amendment hereto signed by the Parties, the Parties agree that this Schedule shall govern compensation from AmericaTowne
to the Service Provider for providing those services set forth in the Agreement.

 

NOW, THEREFORE, in consideration
the representations, warranties and agreements herein contained, the Parties agree as follows:

 

1.       Support
Services. Subject to the disclosures set forth in Section 3 and Section 4 of this Schedule, during the Term and, if applicable,
the Option Term, as these terms are defined in the Agreement, AmericaTowne shall pay the Service Provider:

a) Solely at AmericaTowne’s
discretion a fee equal to 1.0% to 13% of the gross

value of all funds, insurance, loans and or guarantees charged and collected from those businesses and individuals participating
or contracting with AmericaTowne export program;

b) A stock award of 25,000 shares
of AmericaTowne’s commons stock one year after this agreement is signed and it is still in force and affect;

c) Starting at the end of the third
month, provided that the Service provider has met the production schedule, a monthly stipend $1,600.00 paid solely at the discretion
of AmericaTowne; and

d) A stock option of 25,000 shares
of commons stock of AmericaTowne for each year the

agreement is in force for up to five years. Starting in the year 2016 and each year thereafter, the option can be exercised annually
in the month of December on or before the 31st of December at the option price of $1.50 per common share.

           

2.       In
addition, the Service Provider agrees to pay AmericaTowne a nonrefundable service fee of $35,000.00 USD on the Effective Date
(the "Service Fee"). The Service Fee is recognized when deliverables are provided. The Service Fee is paid for
deliverables including the formation and registration of the LLC, recording the Service Provider’s ownership interest
in the newly formed entity, and the delivery of marketing materials to be used by the Service Provider. The Service Fee is to
be paid as follows: $1,000 upon signing this agreement; and monthly payments of $500 a month for sixty-eight months. The
first monthly payment will start on 30 May 2017, and run for 68 consecutive months. At the discretion of AmericaTowne Inc.
the Service Provider may be required to sign a note for outstanding service fees. In addition, AmericaTowne Inc. at its sole
discretion may exchange other assets or items of value for payments due. The Service Provider shall be given credit for any
and all funds paid pursuant to this agreement.

 

3.       The
Service Provider Is Not A Real Estate Broker. AmericaTowne agrees that the Service Provider is not being compensated as a
real estate broker or salesperson as the Service Provider is not licensed as such a broker or salesperson, and the Service Provider
shall not sell or offer for sale, buy or offer to buy, provide or offer to provide market analyses, list or offer or attempt to
list, or negotiate the purchase or sale or exchange or mortgage of real estate, and AmericaTowne acknowledges and agrees that
it will retain its own attorneys, accountants and real estate brokers and/or salespeople, as needed, for any transactions contemplated
under the Agreement and this Schedule.

 

    -1-
 

    

    

 

 

4.       The
Service Provider Is Not A Securities Broker or Dealer. AmericaTowne agrees that the Service Provider is not being compensated
as a broker/dealer or registered FINRA representative in the business of selling securities. AmericaTowne acknowledges that the
Agreement and this Schedule is limited solely to consulting and advisory services, and AmericaTowne agrees that the compensation
set forth herein shall be categorized as valuable consideration in the context of facilitating the services under the Agreement,
and payment of any consideration under this Schedule constitutes a waiver and release of any claims by AmericaTowne that the payment
is related in any manner to the sale of securities.

 

5.       Merger
and Integration. This Schedule, along with the Agreement, contain the entire agreements of the Parties, and any and all prior
schedules, agreements, representations, promises or, to the extent recognized by a court of competent jurisdiction to constitute
binding duties and obligations under North Carolina law, are superseded by and/or merged into the aforementioned agreements.

 

6.       Miscellaneous.
The Parties agree that all other remaining provisions set forth in the Agreement are incorporated by reference as if fully stated
herein.

 

IN WITNESS WHEREOF, the
parties hereto have caused this Schedule to be executed and delivered as of the date set forth above.

 

 

	
        AMERICATOWNE, INC.

         

        By:/s/Alton Perkins

        Alton Perkins

        Chairman of the Board

        Authorized by Board of Directors

         
	Date 3/27/2017
	
        THE SERVICE PROVIDER

         

         

        By:/s/ Mr. Mabiala Phuati Josue

        Mr. Mabiala Phuati Josue 
	Date 3/27/2017

 

 

    -2-gkos_Ex10_1

		
			Exhibit 10.1
		

		
			FIRST AMENDMENT OF
		

		
			AMENDED AND RESTATED PATENT LICENSE AGREEMENT
		

		
			THIS FIRST AMENDMENT OF AMENDED AND RESTATED PATENT LICENSE AGREEMENT (the “First Amendment”) is entered into and effective as of this 12th day of April, 2017 (the "First Amendment Date") by and between GLAUKOS CORPORATION, a Delaware corporation ("GLAUKOS") and DOSE MEDICAL CORPORATION, a Delaware corporation ("DOSE").
		

		
			RECITALS
		

		
			A.         GLAUKOS and DOSE are parties to that certain Amended and Restated Patent License Agreement dated as of June 30, 2015 (the “Agreement”); and
		

		
			B.         Concurrently herewith, the parties have entered into a certain IOP System Purchase Agreement pursuant to which GLAUKOS has purchased certain assets and assumed certain liabilities of DOSE related to DOSE’s "IOP System" (as defined therein).
		

		
			C.         Consistent with the IOP System sale to GLAUKOS described above, the parties desire to amend the Agreement as expressly set forth below.
		

		
			NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:
		

		
			1.         AMENDMENTS.
		

		
			1.1.      Section 1.2 of the Agreement is hereby amended in its entirety as follows:
		

		
			1.2         [Intentionally Omitted].
		

		
			1.2       Section 1.4 of the Agreement is hereby amended in its entirety as follows:
		

		
			1.4         "Dose Field of Use" means any and all applications for the treatment of any disorder or disease (other than Glaucoma) primarily affecting the posterior segment of the eye (i.e. the back two-thirds of the eye that includes the anterior hyaloid membrane and all of the optical structures behind it: the vitreous humor, retina, choroid, and optic nerve), provided that such applications do not include an apparatus that includes a drainage lumen unless the drainage lumen’s primary purpose is to relieve intraocular pressure caused by the administration of steroids, delivered by an apparatus implanted in or on the eye, to treat a disorder or disease primarily affecting the posterior segment of the eye and not associated with Glaucoma.
		

		
			
		

		
			

		 

 

		

		
			1.3       Section 1.7 of the Agreement is hereby amended in its entirety as follows:
		

		
			1.7         “Glaukos Field of Use” means any and all applications for the treatment of (i) Glaucoma, including but not limited to therapies directed toward reducing intraocular pressure and/or reducing the death of retinal ganglion cells (i.e., neuroprotection) associated with Glaucoma) and/or (ii) any disorder or disease primarily affecting the anterior segment of the eye (i.e., the front third of the eye that includes the structures in front of the vitreous humor: the cornea, iris, ciliary body, the lens, the anterior chamber between the posterior surface of the cornea and the iris and the posterior chamber between the iris and the front face of the vitreous).
		

		
			1.4       Section 3.2 of the Agreement is hereby amended in its entirety as follows:
		

		
			3.2         Neither DOSE nor its sublicensees shall seek or obtain a label indication in any country for the treatment of any disorder or disease affecting the anterior segment of the eye for any product whose manufacture, use, offer for sale, sale or importation in or to such country would (absent the license granted under Section 3.1 above) infringe a Valid Claim of a Glaukos Group 1 Licensed Patent.
		

		
			1.5       Exhibits A, B, C is hereby amended in its entirety as set forth on Exhibit A, B, C attached to this First Amendment.
		

		
			2.         SCOPE OF AMENDMENT.  This First Amendment amends the Agreement as expressly provided herein and, as expressly amended hereby, the Agreement continues in full force and effect.
		

		
			3.         DEFINITIONS.  Capitalized terms used in this First Amendment shall have the same meanings as set forth in the Agreement, unless otherwise defined herein.
		

		
			[Remainder of Page Intentionally Omitted]
		

		
			
		

		
			

		 

 

		

		
			IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to be executed effective as of the First Amendment Date.
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						GLAUKOS CORPORATION

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						/s/Thomas W. Burns

				
	
					
						 

					
					
						Print Name:

					
					
						Thomas W. Burns

				
	
					
						 

					
					
						Title:

					
					
						CEO

				

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						DOSE MEDICAL CORPORATION

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						/s/Bruce Nogales

				
	
					
						 

					
					
						Print Name:

					
					
						Bruce Nogales

				
	
					
						 

					
					
						Title:

					
					
						Pres. and CEO

				

		
			 
		

		
			[Signature Page to First Amendment to Patent License Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]